Literature DB >> 1294515

Optimal characteristics of agents to treat uncomplicated urinary tract infections.

H C Neu1.   

Abstract

The optimal characteristics of agents to treat uncomplicated urinary tract infection must include activity against the major pathogens involved in these infections as well as a low potential for development of bacterial resistance. High urinary levels should be present for an adequate period to eliminate the organisms. Side effects should be minimal with minimal effect on the bacterial flora of the community. Treatment programs of single-dose, three days, or five days can be developed depending upon the agent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1294515     DOI: 10.1007/bf01710012

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  41 in total

1.  Chemotherapeutic and antibiotic drugs in the management of infections of the urinary tract.

Authors:  E H KASS
Journal:  Am J Med       Date:  1955-05       Impact factor: 4.965

Review 2.  Short-term treatment of uncomplicated lower urinary tract infections in women.

Authors:  S R Norrby
Journal:  Rev Infect Dis       Date:  1990 May-Jun

Review 3.  The quinolones.

Authors:  H C Neu
Journal:  Infect Dis Clin North Am       Date:  1989-09       Impact factor: 5.982

4.  The role of introital enterobacteria in recurrent urinary infections.

Authors:  T A Stamey
Journal:  J Urol       Date:  1973-03       Impact factor: 7.450

5.  Comparison of single dose netilmicin with a five-day course of co-trimoxazole for uncomplicated urinary tract infections.

Authors:  R R Bailey; E Blake; B A Peddie
Journal:  N Z Med J       Date:  1984-04-25

6.  Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents.

Authors:  N A Carlone; M Borsotto; A M Cuffini; D Savoia
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

7.  Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries.

Authors:  B E Murray; T Alvarado; K H Kim; M Vorachit; P Jayanetra; M M Levine; I Prenzel; M Fling; L Elwell; G H McCracken
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

8.  A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose.

Authors:  A Jardin
Journal:  Infection       Date:  1990       Impact factor: 3.553

9.  Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study.

Authors:  K G Naber; U Thyroff-Friesinger
Journal:  Infection       Date:  1990       Impact factor: 3.553

Review 10.  Use of quinolones in treatment of prostatitis and lower urinary tract infections.

Authors:  V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

View more
  5 in total

1.  Management of uncomplicated urinary tract infections.

Authors:  Timothy Jancel; Vicky Dudas
Journal:  West J Med       Date:  2002-01

Review 2.  Quinolones for uncomplicated acute cystitis in women.

Authors:  V Rafalsky; I Andreeva; E Rjabkova
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 3.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

4.  Effect of norfloxacin therapy for acute, uncomplicated lower urinary tract infection on vaginal Candida prevalence.

Authors:  Rodrigo M Rocha; Pâmela C M Delvas Zanni; Patrícia de Souza Bonfim-Mendonça; Fabrícia Gimenes; Silvia S Dantas Alczuk; Terezinha I Estivalet Svidzinski; Márcia E Lopes Consolaro
Journal:  Int Urogynecol J       Date:  2015-11-13       Impact factor: 2.894

5.  The Good and the Bad: Ecological Interaction Measurements Between the Urinary Microbiota and Uropathogens.

Authors:  Laurens E Zandbergen; Thomas Halverson; Jolanda K Brons; Alan J Wolfe; Marjon G J de Vos
Journal:  Front Microbiol       Date:  2021-05-10       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.